Trial Profile
A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Agammaglobulinaemia; Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors ADMA Biologics; Biotest Pharmaceuticals
- 30 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2021 Planned End Date changed from 30 Jun 2021 to 31 Dec 2022.